|
Sign In to gain access to subscriptions and/or personal tools.
|
NAUTILUS (Safety and tolerability of Niaspan®): a subgroup analysis in patients with diabetes
Anja Vogt
Charite-Universitätsmedizin Berlin, Germany
Ursula Kassner
Charite-Universitätsmedizin Berlin, Germany
Ulrike Hostalek
Merck KGaA, Darmstadt, Germany
Elisabeth Steinhagen-Thiessen
Charite-Universitätsmedizin Berlin, Germany, Elisabeth.steinhagen-thiessen{at}charite.de
The multiceNtre, open, uncontrolled sAfety and tolerability stUdy of a modified-release nicoTinic acId formuLation in sUbjects with dySlipidaemia and low HDL-cholesterol (NAUTILUS) trial was designed to evaluate the safety and tolerability of prolonged-release nicotinic acid (Niaspan®) in patients treated for dyslipidaemia in a usual care setting in Germany. The dyslipidaemia was inadequately controlled by diet, including low high-density lipoprotein cholesterol (HDL-C) (< 1.0 mmol/L [< 40 mg/dL] in men and < 1.2 mmol/L [<46 mg/dL] in women). This analysis focuses on the tolerability and safety of Niaspan® in patients with diabetes. Diabetic and non-diabetic subjects reported similar incidences of all-cause adverse events (AE; 59.9% vs. 60.8%, respectively), serious AE (SAE; 4.0% vs. 3.4%, respectively) and withdrawals for AE (17.6% vs. 16.4%). Flushing was the most common side effect, as expected (42% of patients in each group), but < 10% withdrew for flushing. There was no indication of hepatotoxicity or serious muscle toxicity in diabetic or non-diabetic subjects. Changes in glycaemic parameters were small (mean changes in diabetic subjects of +0.2% HbA1C and +0.4 mmol/L [+8 mg/dL] for fasting plasma glucose), despite marked reductions in the intensity of antidiabetic therapy in about one third of patients. Niaspan® was equally effective in diabetic or non-diabetic subjects in increasing HDL-C (+24% in each group) and decreasing triglycerides (-12% and -13%, respectively). Niaspan® was well tolerated in patients with type 2 diabetes and the results of NAUTILUS support its use for correction of low HDL-C in this population.
Key Words: diabetes • prolonged-release nicotinic acid • Niaspan® • dyslipidaemia • HDL-C • safety.
References
- Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- International Diabetes Federation. IDF worldwide definition of the metabolic syndrome. Available at www.idf.org (last accessed July 2005).
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;17:106:3143-421.
- Gordon T., Kannel WB, Castelli WP, Dawber TR Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981; 141:1128-31. 5. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.[Abstract/Free Full Text]
- Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl):S11-S20.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet 2004;364:937-52.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Goldbourt U., Yaari S., Medalie JH Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13.[Abstract/Free Full Text]
- Brown G., Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.[Abstract]
- Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17.[Abstract/Free Full Text]
- Brown BG, Zhao X.-Q, Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.[Abstract/Free Full Text]
- Rubins HB, Robins SJ, Iwane MK et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993;71:45-52.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Brown BG Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J 2005;7(suppl F): F34-F40.[CrossRef]
- McGovern ME Niaspan®: creating a new concept for raising HDLcholesterol. Eur Heart J 2005;7(suppl F):F41-F47.[CrossRef]
- Krauss RM Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.[Abstract/Free Full Text]
- Knopp RH, Alagona P., Davidson M. et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Abourjaily HM A review of Niaspan, an extended-release niacin. Nutr Clin Care 2001;4:250-5.[CrossRef]
- Guyton JR Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-98.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Vogt A., Kassner U., Hostalek U., Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS Study. Curr Med Res Opin 2006;22:417-25.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162: 1568-76.[Abstract/Free Full Text]
- Grundy SM, Vega GL, McGovern ME et al. Comparative effects on lipids and glycemic control of niacin extended-release/lovastatin or fenofibrate in patients with diabetic dyslipidemia. Abstract 29-LB, presented at the 64th Scientific Sessions of the American diabetes Association, June 4-8 2004, Orlando, Florida, USA.
The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3,
127-133 (2006)
DOI: 10.1177/14746514060060030501
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
